Table 3 Ongoing clinical trials of EZH2 inhibitors
From: Clinical advances in epigenetic therapies for lymphoma
Clinical trial | Therapeutic agent | Key study population |
|---|---|---|
SYMPHONY-1 Phase 1b/3 NCT04224493 [86] | Tazemetostat + lenalidomide + rituximab | R/R FL |
SYMPHONY-2 Phase 2 NCT04762160 [87] | Tazemetostat + rituximab | R/R FL |
Phase 1/2 NCT01897571 | Tazemetostat + prednisolone | Advanced solid tumors (single-agent tazemetostat) R/R DLBCL (combination therapy) |
Phase 2 NCT04842877 | Valemetostat | R/R aggressive B cell lymphomas, transformed indolent lymphoma, FL, MCL, MZL, HL |
Phase 1/2 NCT04104776 | CPI-0209 | Advanced solid tumors R/R DLBCL |
Phase 1 NCT04390737 | HH2853 | Advanced solid tumors R/R DLBCL, FL |
Phase 1 NCT03460977 | PF-06821497 | R/R SCLC (combination therapy with SOC), CRPC (combination therapy with SOC), FL (single agent), DLBCL (single agent) |